Breaking News

Forge Biologics Receives PRIME Designation from EMA for Novel Gene Therapy

PRIME designation granted to drug candidates that may offer a major therapeutic advantage over existing treatments.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), said that the European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge’s lead adeno-associated virus (AAV) drug candidate and novel gene therapy for treating patients with Krabbe disease. PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance and speed up their developmen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters